Lazard Capital Raises Abiomed to Buy (ABMD)
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated an “outperform” rating on shares of Abiomed in a research note to investors on Monday, May 28th. They now have a $25.00 price target on the stock. Separately, analysts at MKM Partners raised their price target on shares of Abiomed from $27.00 to $29.00 in a research note to investors on Thursday, May 17th. They now have a “buy” rating on the stock. Finally, analysts at Wunderlich raised their price target on shares of Abiomed from $27.00 to $29.00 in a research note to investors on Thursday, May 17th. They now have a “buy” rating on the stock.
Abiomed traded up 3.09% on Monday, hitting $20.38. Abiomed has a 1-year low of $9.98 and a 1-year high of $26.17. The company has a market cap of $791.6 million and a price-to-earnings ratio of 494.25.
Abiomed last released its earnings data on Wednesday, May 16th. The company reported $0.07 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.07. The company’s quarterly revenue was up 30.9% on a year-over-year basis. Analysts expect that Abiomed will post $0.04 EPS next quarter.
Abiomed, Inc. is a provider of medical devices in circulatory support and offers a continuum of care in heart recovery to acute heart failure patients.